Tislelizumab
- Generic Name
- Tislelizumab
- Brand Names
- Tevimbra, Tizveni
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1858168-59-8
- Unique Ingredient Identifier
- 0KVO411B3N
- Background
Tislelizumab is under investigation in clinical trial NCT02660034 (The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors).
- Indication
⑴用于治疗至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤（R/R cHL）患者。
⑵用于治疗局部晚期或转移性尿路上皮癌。
⑶联合化疗用于治疗一线晚期非鳞状非小细胞肺癌（NSCLC）患者。
⑷用于治疗既往接受过治疗的不可切除肝细胞癌患者。
⑸用于治疗晚期恶性实体瘤
- Associated Conditions
- -
- Associated Therapies
- -
A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 21
- Registration Number
- NCT06741982
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2024-12-16
- Target Recruit Count
- 430
- Registration Number
- NCT06704620
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Immunobridging/Maintenance Therapy Versus Non-bridging Therapy in CAR-T Therapy for Low-risk R/R B-NHL
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-19
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 144
- Registration Number
- NCT06695013
- Locations
- 🇨🇳
Ruijin, Shanghai, Shanghai, China
Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS
Phase 2
Not yet recruiting
- Conditions
- Interventions
- Drug: Albumin-Bound PaclitaxelDrug: OtherDrug: EpirubicinDrug: GemcitabineDrug: VinorelbineDrug: CisplatinDrug: IrinotecanDrug: FluorouracilDrug: NivolumabDrug: PembrolizumabDrug: DurvalumabDrug: AtezolizumabDrug: SintilimabDrug: TislelizumabDrug: CamrelizumabDrug: ToripalimabDrug: SerplulimabDrug: AdebrelimabDrug: EnvafolimabDrug: OsimertinibDrug: AlectinibDrug: VemurafenibDrug: PamiparibDrug: PyrotinibDrug: ImatinibDrug: PalbociclibDrug: SavolitinibDrug: Entrectinib
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Peking University Shenzhen Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT06692491
Tislelizumab as Single-Agent Neoadjuvant Immunotherapy in Resectable Esophageal Squamous Cell Carcinoma
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Not specified
- Target Recruit Count
- 20
- Registration Number
- NCT06692270
Tislelizumab Combined with SBRT for the Treatment of Head and Neck Squamous Cell Carcinoma
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-05
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 24
- Registration Number
- NCT06673693
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-26
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT06659042
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal Squamous Cell Carcinoma
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-17
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Hebei Medical University Fourth Hospital
- Target Recruit Count
- 67
- Registration Number
- NCT06646588
- Locations
- 🇨🇳
Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC
Not Applicable
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2024-09-23
- Lead Sponsor
- Xuanwu Hospital, Beijing
- Target Recruit Count
- 40
- Registration Number
- NCT06607926
- Locations
- 🇨🇳
Xuanwu Hospital, Capital Medical University, Beijing, China
Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumav Plus Platinum-based Chemotherapy As Neoadjuvant Therapy in Patients with Resectable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer: a Phase Ⅲ, Randomized, Multicenter, Prospective Study
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-09-19
- Lead Sponsor
- Yang Hong
- Target Recruit Count
- 360
- Registration Number
- NCT06598527
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath